Hims & Hers is broadening treatment options for the 20 million men dealing with low testosterone with a new oral pill and an injectable set for 2026
Telehealth platform Hims & Hers has launched an exclusive white label oral testosterone treatment through a partnership with Marius Pharmaceuticals, introducing a needle-free, FDA-approved option for millions of men struggling with low testosterone.
Injectable testosterone will be added to the platform in 2026, giving men another option for care, Hims confirmed.
The collaboration centers on Kyzatrex, an FDA-approved oral testosterone shown in clinical trials to restore testosterone levels in up to 96% of men and double free testosterone, the form associated with energy and drive.
“Low testosterone care has been stuck in the past, stigmatized, expensive and inaccessible for most men,” Hims & Hers founder and CEO Andrew Dudum said. “We’re bringing it into the future with treatments that are easy to access and designed around each individual. This isn’t just about one product, it’s about addressing a condition that fundamentally changes how millions of men will feel and show up in life and about building an entirely new model of care that they can finally rely on.”
As part of the rollout, customers start with an at-home blood test and connect with licensed providers through the Hims platform. Providers can prescribe tailored doses of compounded enclomiphene, a treatment that restores natural testosterone production without affecting fertility. For men with sexual symptoms, providers may also recommend a dual-action option that combines enclomiphene with tadalafil, a prescription medication used to treat erectile dysfunction.
The launch comes as women’s care, particularly hormone health tied to perimenopause and menopause, has drawn growing attention from startups and major health players. Recent moves include WeightWatchers’ menopause program and Midi Health’s partnership with Club Pilates and Pure Barre, two of Xponential’s leading boutique fitness brands.
Similar to how women navigating perimenopause and menopause often feel overlooked or isolated, an estimated 20 million in the U.S. live with low testosterone and avoid treatment due to societal stigmas and cost barriers. Left untreated, Hims says it can sap energy, dampen mood and sexual desire and raise the risk of heart disease, diabetes and cancer.
“Marius developed Kyzatrex to modernize testosterone replacement therapy with an oral treatment backed by rigorous science and FDA approval,” Marius Pharmaceuticals CEO Shalin Y. Shah said. “Partnering with Hims & Hers allows us to bring this innovation to scale. Their platform has proven reach, accessibility and trust with millions of customers, making them the perfect partner to expand access to Kyzatrex and redefine what’s possible in men’s hormone health.”
